CF602 / Can-Fite - LARVOL DELTA

A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model. (PubMed, Andrologia) - "A significant increase in smooth muscle:collagen ratio, vascular endothelial growth factor and endothelial nitric oxide synthase was also observed in both administration modes. In conclusion, topical and oral treatment with CF602 significantly improved erectile function, supporting its further evaluation as a treatment for ED."

Journal • Preclinical • Erectile Dysfunction

[VIRTUAL] Can-Fite BioPharma (BIO 2021) - "The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH)...CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date."

Colorectal Cancer • Dermatology • Erectile Dysfunction • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cancer • Melanoma • Non-alcoholic Steatohepatitis • Novel Coronavirus Disease • Oncology • Psoriasis • Solid Tumor

"Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model https://t.co/FecrOb4fNU" (@NewsFromBW)

Erectile Dysfunction